AR016294A1 - Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion - Google Patents
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacionInfo
- Publication number
- AR016294A1 AR016294A1 ARP980103180A ARP980103180A AR016294A1 AR 016294 A1 AR016294 A1 AR 016294A1 AR P980103180 A ARP980103180 A AR P980103180A AR P980103180 A ARP980103180 A AR P980103180A AR 016294 A1 AR016294 A1 AR 016294A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- heteroaryl
- cr10r20
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Un compuesto de imidazol sustituido porque está representado por la formula (I) en la que: R1 es un anillo de 4-piridilo, pirimidinilo, 4-piridazinilo,1,2,4-triazin-5-ilo, quinolilo, isoquinolilo o quinazolin-4-ilo, cuyo anillo está sustituido con Y-Ra y opcionalmente con un sustituyente independienteadicional, seleccionado entre alquilo C1-4, halogeno, hidroxilo, alcoxi C1-4, alquiltio C1-4, alquilsulfinilo C1-4, CH2OR12, amino, amino mono- y di-sustituido con alquilo C1-6, un anillo de N-heterociclilo, cuyo anillo tiene de 5 a 7 miembros y contiene opcionalmente un heteroátomo adicional seleccionadoentre oxígeno, azufre o NR15, N(R10)C(O)Rb o NHRa; Y es oxígeno o azufre; R4 es fenilo, naft-1-ilo o naft-2-ilo, o un heteroarilo, que opcionalmente estásustituido con uno o dos sustituyentes, cada uno de los cuales se selecciona independientemente, y que, para un sustituyente de 4-fenilo, 4-naft-1-ilo,5-naft-2-ilo o 6-naft-2-ilo, es halogeno, ciano, nitro, C(Z)NR7R17, C(Z)OR16, (CR10R20)vCOR12, SR5, SOR5, OR12, alquilo C1-4 sustituido con halo, alquiloC1-4, ZC(Z)R12, NR10C(Z)R16 o (CR10R20)vNR10R20 y que, para otras posiciones de sustitucion, es halogeno, ciano, C(Z)NR13R14, C(Z)OR3, (CR10R20)mCOR3, S(O)mR3, OR3, alquilo C1-4 sustituido con halo, alquilo C1-4, (CR10R20)mNR10C(Z)R3, NR10S(O)mR8, NR10S(O)mNR7R17, ZC(Z)R3 o (CR10R20)mNR13R14; Z es oxígenoo azufre; n es un numero entero que tiene un valor de 1 a 10; m es 0 o el numero entero 1 o 2; m es un numero entero que tiene un valor de 1 o 2; m es 0, oun numero entero que tiene un valor de 1 a 5; v es 0, o un numero entero que tiene un valor de 1 o 2; R2 es -C(H)(A)(R22); A es un anillo de arilo,heterociclico o heteroarilo opcionalmente sustituido, o A es un alquilo C1-10 sustituido; R22 es un alquilo C1-10 opcionalmente sustituido; Ra es arilo,aril-alquilo C1-6, heterociclilo, heterociclil-alquilo C1-6, heteroarilo o heteroaril-alquilo C1-6, pudiendo cada uno de estos restos estar opcionalmentesustituido; Rb es hidrogeno, alquilo C1-6, cicloalquilo C3-7, arilo, arilalquilo C1-4, heteroarilo, heteroaril-alquilo C1-4, heterociclilo o
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5159297P | 1997-07-02 | 1997-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR016294A1 true AR016294A1 (es) | 2001-07-04 |
Family
ID=21972242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980103180A AR016294A1 (es) | 1997-07-02 | 1998-06-30 | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP0996446B1 (es) |
JP (2) | JP2002507994A (es) |
KR (1) | KR20010014420A (es) |
CN (1) | CN1134420C (es) |
AR (1) | AR016294A1 (es) |
AT (1) | ATE290001T1 (es) |
AU (1) | AU8381298A (es) |
BR (1) | BR9810342A (es) |
CA (2) | CA2294522A1 (es) |
CO (1) | CO4950624A1 (es) |
CZ (1) | CZ9904750A3 (es) |
DE (2) | DE69829192T2 (es) |
ES (2) | ES2237843T3 (es) |
HU (1) | HUP0002050A3 (es) |
IL (3) | IL133035A0 (es) |
NO (1) | NO996572D0 (es) |
NZ (1) | NZ500922A (es) |
PL (1) | PL337738A1 (es) |
TR (1) | TR200000014T2 (es) |
TW (1) | TW536539B (es) |
WO (2) | WO1999001130A1 (es) |
ZA (1) | ZA985763B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5916891A (en) | 1992-01-13 | 1999-06-29 | Smithkline Beecham Corporation | Pyrimidinyl imidazoles |
US6979686B1 (en) | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
AU7966198A (en) | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
AU8154998A (en) | 1997-06-19 | 1999-01-04 | Smithkline Beecham Corporation | Novel aryloxy substituted pyrimidine imidazole compounds |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6362193B1 (en) | 1997-10-08 | 2002-03-26 | Smithkline Beecham Corporation | Cycloalkenyl substituted compounds |
US6599910B1 (en) | 1998-08-20 | 2003-07-29 | Smithkline Beecham Corporation | Substituted triazole compounds |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
ES2230171T3 (es) | 1999-11-23 | 2005-05-01 | Smithkline Beecham Corporation | Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa. |
US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
EP1534282B1 (en) | 2002-07-09 | 2006-12-27 | Boehringer Ingelheim Pharma GmbH & Co.KG | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
EP1560488B1 (en) | 2002-11-05 | 2010-09-01 | Glaxo Group Limited | Antibacterial agents |
AU2004298486A1 (en) | 2003-12-12 | 2005-06-30 | Wyeth | Quinolines useful in treating cardiovascular disease |
TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
KR100793479B1 (ko) * | 2004-04-28 | 2008-01-14 | 다나베 미츠비시 세이야꾸 가부시키가이샤 | 염증성 질환을 치료하기 위한 p38 MAP- 키나제억제제로서의4-2-(시클로알킬아미노)피리딘-4-일-(페닐)-이미다졸린-2-온 유도체 |
TWI326282B (en) | 2004-04-28 | 2010-06-21 | Mitsubishi Tanabe Pharma Corp | Heterocyclic compound |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
WO2006062110A1 (ja) * | 2004-12-06 | 2006-06-15 | Banyu Pharmaceutical Co., Ltd. | ピペラジン誘導体 |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2007049820A1 (ja) | 2005-10-28 | 2007-05-03 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物及びその用途 |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
CN104955459B (zh) * | 2012-11-05 | 2019-02-01 | 南特知识产权控股有限责任公司 | 取代的吲哚-5-酚衍生物及其治疗应用 |
NZ762856A (en) | 2017-10-05 | 2020-07-31 | Fulcrum Therapeutics Inc | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US20230271953A1 (en) * | 2019-11-29 | 2023-08-31 | Facio Intellectual Property B.V. | Novel compounds for treatment of diseases related to DUX4 expression |
CN115151256A (zh) * | 2019-11-29 | 2022-10-04 | Facio知识产权有限公司 | 用于治疗与dux4表达相关的疾病的新化合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ188244A (en) * | 1977-09-13 | 1981-04-24 | Ici Australia Ltd | 2-substituted pyrimidines compositions growth regulating processes |
GR75287B (es) * | 1980-07-25 | 1984-07-13 | Ciba Geigy Ag | |
US4503065A (en) * | 1982-08-03 | 1985-03-05 | E. I. Du Pont De Nemours And Company | Antiinflammatory 4,5-diaryl 1-2-halo imidazoles |
US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
JPH082883B2 (ja) * | 1986-06-06 | 1996-01-17 | クミアイ化学工業株式会社 | 2−フエノキシピリミジン誘導体および除草剤 |
IL83467A0 (en) * | 1986-08-15 | 1988-01-31 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same |
US5593991A (en) * | 1993-07-16 | 1997-01-14 | Adams; Jerry L. | Imidazole compounds, use and process of making |
US5670527A (en) * | 1993-07-16 | 1997-09-23 | Smithkline Beecham Corporation | Pyridyl imidazole compounds and compositions |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
PL321292A1 (en) * | 1995-01-12 | 1997-11-24 | Smithkline Beecham Corp | Novel xchemical compounds |
US5658903A (en) * | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
CA2242327A1 (en) * | 1996-01-11 | 1997-07-17 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
US6372741B1 (en) * | 1996-03-08 | 2002-04-16 | Smithkline Beecham Corporation | Use of CSAID™ compounds as inhibitors of angiogenesis |
WO1997035856A1 (en) * | 1996-03-25 | 1997-10-02 | Smithkline Beecham Corporation | Novel treatment for cns injuries |
-
1998
- 1998-06-30 AR ARP980103180A patent/AR016294A1/es not_active Application Discontinuation
- 1998-07-01 EP EP98934244A patent/EP0996446B1/en not_active Expired - Lifetime
- 1998-07-01 CA CA002294522A patent/CA2294522A1/en not_active Abandoned
- 1998-07-01 CO CO98037026A patent/CO4950624A1/es unknown
- 1998-07-01 NZ NZ500922A patent/NZ500922A/en unknown
- 1998-07-01 AT AT98934247T patent/ATE290001T1/de not_active IP Right Cessation
- 1998-07-01 BR BR9810342-3A patent/BR9810342A/pt not_active Application Discontinuation
- 1998-07-01 ES ES98934247T patent/ES2237843T3/es not_active Expired - Lifetime
- 1998-07-01 ZA ZA985763A patent/ZA985763B/xx unknown
- 1998-07-01 DE DE69829192T patent/DE69829192T2/de not_active Expired - Fee Related
- 1998-07-01 IL IL13303598A patent/IL133035A0/xx unknown
- 1998-07-01 HU HU0002050A patent/HUP0002050A3/hu active IP Right Revival
- 1998-07-01 JP JP50738999A patent/JP2002507994A/ja active Pending
- 1998-07-01 WO PCT/US1998/013809 patent/WO1999001130A1/en active Application Filing
- 1998-07-01 AU AU83812/98A patent/AU8381298A/en not_active Abandoned
- 1998-07-01 CA CA002294524A patent/CA2294524A1/en not_active Abandoned
- 1998-07-01 TR TR2000/00014T patent/TR200000014T2/xx unknown
- 1998-07-01 EP EP98934247A patent/EP1014976B1/en not_active Expired - Lifetime
- 1998-07-01 JP JP50738599A patent/JP2002507992A/ja active Pending
- 1998-07-01 CN CNB988066440A patent/CN1134420C/zh not_active Expired - Fee Related
- 1998-07-01 CZ CZ19994750A patent/CZ9904750A3/cs unknown
- 1998-07-01 WO PCT/US1998/013805 patent/WO1999001131A1/en active IP Right Grant
- 1998-07-01 KR KR1019997012604A patent/KR20010014420A/ko not_active Application Discontinuation
- 1998-07-01 PL PL98337738A patent/PL337738A1/xx unknown
- 1998-07-01 ES ES98934244T patent/ES2207847T3/es not_active Expired - Lifetime
- 1998-07-01 DE DE69818266T patent/DE69818266T2/de not_active Expired - Fee Related
- 1998-08-27 TW TW087110613A patent/TW536539B/zh not_active IP Right Cessation
-
1999
- 1999-12-30 NO NO996572A patent/NO996572D0/no not_active Application Discontinuation
-
2008
- 2008-03-17 IL IL190215A patent/IL190215A0/en unknown
- 2008-03-17 IL IL190216A patent/IL190216A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR016294A1 (es) | Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion | |
AR013172A1 (es) | Compuestos de imidazol sustituido, composicion farmaceutica que lo contiene, el uso del mismo en la manufactura de un medicamento y procedimientopara su preparacion | |
AR006307A1 (es) | Compuestos de imidazol 5-piridinil o 5-pirimidinil sustituidos, composicion farmaceutica, uso de dichos compuestos para prepararmedicamentos y procedimiento para preparar dichos compuestos. | |
BR9303993A (pt) | Composto, processo para preparar o mesmo e composição farmacêutica | |
TR200003256T2 (tr) | P-38 mapkinaz engelleyicileri olan pirazol türevleri | |
ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
AR023681A1 (es) | Derivados de tetrahidrobenzazepinas, composiciones farmaceuticas y el uso de los mismos para la manufactura de un medicamento. | |
CO5370680A1 (es) | Nuevos compuestos | |
BR0211427A (pt) | Compostos, processo para preparar os mesmos, composição adequada para combater fungos danosos, uso de compostos, e, processo para combater fungos danosos | |
TR199801942T2 (xx) | Piperazin ve piperidin bile�ikleri. | |
DK0687251T3 (da) | 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister | |
AR028531A1 (es) | Compuestos organicos | |
DK2032589T3 (da) | Opløsningsmiddelsystem til fremstilling af N-alkylthiophosphorsyretriamid-opløsninger, sammensætning, som indeholder N-alkylthiophosphorsyretriamid, og anvendelse deraf | |
DE60100506D1 (de) | 1,3-dihydro-2h-indol-2-on derivate und deren verwendung als liganden der arginin-vasopressin rezeptoren v1b oder v1b und v1a | |
BR0113610A (pt) | Derivados da fenoxibenzilamina como inibidores seletivos de recuperação de serotonina | |
KR960014112A (ko) | 자외선 흡수제, 이의 제조방법 및 용도 | |
AR002711A1 (es) | Un compuesto de 2-carboxindol-3-substituido,un proceso para su preparacion, un nuevo compuesto intermediario para dicho proceso, el uso del compuesto parala fabricacion de un agente terapeutico y una composicion farmaceutica que comprende dicho compuesto. | |
HUP0203722A2 (hu) | Helyettesített fenilpiperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
BR0212716A (pt) | Inibidores de liberação extracelular de citocinas inflamatórias e composição farmacêutica | |
ATE9336T1 (de) | 3,1-benzoxazin-2-one, ihre herstellung und verwendung. | |
ATE26266T1 (de) | Pyridazinone, ihre herstellung und verwendung, pyridazinone enthaltende arzneimittel. | |
BR0113452A (pt) | Derivados de 4-, 5-, 6- e 7- indol úteis para o tratamento de distúrbios do snc, o composto; sua composição farmacêutica e uso do mesmo | |
NO910167D0 (no) | Haarfargemiddel. | |
CY1106317T1 (el) | Παραγωγα 1-ν-φαινυλαμινο-1η-ιμιδαζολης, ως αναστολεις αρωματασης | |
PE20040205A1 (es) | Derivados de azepano como inhibidores de la quinasa akt1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |